$AMGN Headlines Nasdaq breaks out, reaches les
Post# of 144503
Posted On: 08/29/2014 11:32:21 AM
$AMGN Headlines
Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Twitter shines; Fed statement and GDP due today 4:38 a.m. July 30, 2014 - MarketWatch
Amgen plans to cut up to 2,900 jobs 9:04 p.m. July 29, 2014 - MarketWatch.com
Twitter soars 33% in after hours as results surprise on upside 4:56 p.m. July 29, 2014 - Sue Chang
What Makes OncoMed Pharmaceuticals (OMED) a Strong Sell? - Tale of the Tape 8:28 a.m. Today - Zacks.com
Today's Market: Red Hot Biotech And Big Pharma Names To Watch 8:22 a.m. Today - Seeking Alpha
Amgen's Chronic Heart Failure Drug Gets Priority Review - Analyst Blog 6:20 p.m. Aug. 28, 2014 - Zacks.com
Aegerion Resolves FDA's Warning on Juxtapid, Lifts Overhang - Analyst Blog 5:50 p.m. Aug. 28, 2014 - Zacks.com
MediciNova Rises on FDA's Nod on MN-166 Study Initiation - Analyst Blog 5:00 p.m. Aug. 28, 2014 - Zacks.com
BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study - Analyst Blog 4:35 p.m. Aug. 28, 2014 - Zacks.com
Repros Reports Encouraging Late-Stage Data on Androxal - Analyst Blog 4:30 p.m. Aug. 28, 2014 - Zacks.com
Amgen cholesterol-lowering therapeutic candidate succeeds in Phase 3 trial 10:09 a.m. Aug. 28, 2014 - Seeking Alpha
Stocks Hitting 52-Week Highs 9:19 a.m. Aug. 28, 2014 - benzinga.com
After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? 2:06 p.m. Aug. 27, 2014 - GuruFocus.com
Return To Behemoth Stocks 10:25 a.m. Aug. 27, 2014 - Seeking Alpha
Amgen Heart Drug Gets FDA Priority 10:12 a.m. Aug. 27, 2014 - The Wall Street Journal Interactive Edition
Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog 9:49 a.m. Aug. 27, 2014 - Zacks.com
Why Amgen Stock Is A Long-Term Investment Opportunity 9:48 a.m. Aug. 27, 2014 - Seeking Alpha
Rising Short Interest in Biotech Stocks 9:42 a.m. Aug. 27, 2014 - 247WallSt.com
Ivabradine gets priority review 9:41 a.m. Aug. 27, 2014 - Seeking Alpha
Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study - Analyst Blog 6:44 p.m. Aug. 26, 2014 - Zacks.com
Drug Maker in High-Stakes Race With Rivals 6:06 p.m. Aug. 26, 2014 - The Wall Street Journal Interactive Edition
Regado Slumps on Permanent Termination of Revolixys Study - Analyst Blog 5:20 p.m. Aug. 26, 2014 - Zacks.com
HCP Boosts Of 29 Years Of Dividend Increases 4:27 p.m. Aug. 26, 2014 - Investors Business Daily
Acquisitions, Appointment, and Vaccine Recommendations - Research Reports on InterMune, Amgen, Johnson & Johnson, Merck and Medtronic 9:30 a.m. Aug. 28, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol 9:15 a.m. Aug. 28, 2014 - PR Newswire - PRF
Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9:00 a.m. Aug. 28, 2014 - PR Newswire - PRF
FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 9:15 a.m. Aug. 27, 2014 - PR Newswire - PRF
Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 4:55 p.m. Aug. 26, 2014 - PR Newswire - PRF
Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier Leonetti Of Amgen And Formerly At Dell 4:15 p.m. Aug. 25, 2014 - PR Newswire - PRF
Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck 9:20 a.m. Aug. 20, 2014 - PR Newswire - PRF
A New Cannabinoid-based Arthritis Therapy in the Making 9:50 a.m. Aug. 19, 2014 - ACCESSWIRE
Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 1:55 a.m. Aug. 19, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis 5:17 p.m. Aug. 18, 2014 - PR Newswire - PRF
Lemelson Capital Says Ligand Pharmaceuticals' $225M Debt Issuance Solidifies Company's Insolvency, Substantially Raises Specter of Bankruptcy 9:15 a.m. Aug. 14, 2014 - PR Newswire - PRF
Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates 4:12 p.m. Aug. 13, 2014 - PR Newswire - PRF
Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma 4:01 p.m. Aug. 13, 2014 - PR Newswire - PRF
Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs 1:07 p.m. Aug. 11, 2014 - PR Newswire - PRF
Amgen Receives CEO Cancer Gold Standard Accreditation 7:00 a.m. Aug. 11, 2014 - BusinessWire - BZX
Critical Alerts For Stratasys, Horizon Pharma, Isis Pharmaceuticals, Amgen, and Discover Financial Services Released By InvestorsObserver 9:31 a.m. Aug. 8, 2014 - PR Newswire - PRF
Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth 9:13 a.m. Aug. 5, 2014 - PR Newswire - PRF
Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies 11:55 a.m. Aug. 4, 2014 - PR Newswire - PRF
Earnings Headlines - Amgen 9:30 a.m. Aug. 4, 2014 - PR Newswire - PRF
Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Twitter shines; Fed statement and GDP due today 4:38 a.m. July 30, 2014 - MarketWatch
Amgen plans to cut up to 2,900 jobs 9:04 p.m. July 29, 2014 - MarketWatch.com
Twitter soars 33% in after hours as results surprise on upside 4:56 p.m. July 29, 2014 - Sue Chang
What Makes OncoMed Pharmaceuticals (OMED) a Strong Sell? - Tale of the Tape 8:28 a.m. Today - Zacks.com
Today's Market: Red Hot Biotech And Big Pharma Names To Watch 8:22 a.m. Today - Seeking Alpha
Amgen's Chronic Heart Failure Drug Gets Priority Review - Analyst Blog 6:20 p.m. Aug. 28, 2014 - Zacks.com
Aegerion Resolves FDA's Warning on Juxtapid, Lifts Overhang - Analyst Blog 5:50 p.m. Aug. 28, 2014 - Zacks.com
MediciNova Rises on FDA's Nod on MN-166 Study Initiation - Analyst Blog 5:00 p.m. Aug. 28, 2014 - Zacks.com
BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study - Analyst Blog 4:35 p.m. Aug. 28, 2014 - Zacks.com
Repros Reports Encouraging Late-Stage Data on Androxal - Analyst Blog 4:30 p.m. Aug. 28, 2014 - Zacks.com
Amgen cholesterol-lowering therapeutic candidate succeeds in Phase 3 trial 10:09 a.m. Aug. 28, 2014 - Seeking Alpha
Stocks Hitting 52-Week Highs 9:19 a.m. Aug. 28, 2014 - benzinga.com
After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? 2:06 p.m. Aug. 27, 2014 - GuruFocus.com
Return To Behemoth Stocks 10:25 a.m. Aug. 27, 2014 - Seeking Alpha
Amgen Heart Drug Gets FDA Priority 10:12 a.m. Aug. 27, 2014 - The Wall Street Journal Interactive Edition
Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog 9:49 a.m. Aug. 27, 2014 - Zacks.com
Why Amgen Stock Is A Long-Term Investment Opportunity 9:48 a.m. Aug. 27, 2014 - Seeking Alpha
Rising Short Interest in Biotech Stocks 9:42 a.m. Aug. 27, 2014 - 247WallSt.com
Ivabradine gets priority review 9:41 a.m. Aug. 27, 2014 - Seeking Alpha
Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study - Analyst Blog 6:44 p.m. Aug. 26, 2014 - Zacks.com
Drug Maker in High-Stakes Race With Rivals 6:06 p.m. Aug. 26, 2014 - The Wall Street Journal Interactive Edition
Regado Slumps on Permanent Termination of Revolixys Study - Analyst Blog 5:20 p.m. Aug. 26, 2014 - Zacks.com
HCP Boosts Of 29 Years Of Dividend Increases 4:27 p.m. Aug. 26, 2014 - Investors Business Daily
Acquisitions, Appointment, and Vaccine Recommendations - Research Reports on InterMune, Amgen, Johnson & Johnson, Merck and Medtronic 9:30 a.m. Aug. 28, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol 9:15 a.m. Aug. 28, 2014 - PR Newswire - PRF
Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9:00 a.m. Aug. 28, 2014 - PR Newswire - PRF
FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 9:15 a.m. Aug. 27, 2014 - PR Newswire - PRF
Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 4:55 p.m. Aug. 26, 2014 - PR Newswire - PRF
Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier Leonetti Of Amgen And Formerly At Dell 4:15 p.m. Aug. 25, 2014 - PR Newswire - PRF
Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck 9:20 a.m. Aug. 20, 2014 - PR Newswire - PRF
A New Cannabinoid-based Arthritis Therapy in the Making 9:50 a.m. Aug. 19, 2014 - ACCESSWIRE
Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 1:55 a.m. Aug. 19, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis 5:17 p.m. Aug. 18, 2014 - PR Newswire - PRF
Lemelson Capital Says Ligand Pharmaceuticals' $225M Debt Issuance Solidifies Company's Insolvency, Substantially Raises Specter of Bankruptcy 9:15 a.m. Aug. 14, 2014 - PR Newswire - PRF
Amgen Issues Voluntary Recall of Aranesp® (darbepoetin alfa) (500 mcg) Prefilled Syringes in Several Countries Outside of the United States Due to the Presence of Visible Particulates 4:12 p.m. Aug. 13, 2014 - PR Newswire - PRF
Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis® In Patients With Relapsed And Advanced Refractory Multiple Myeloma 4:01 p.m. Aug. 13, 2014 - PR Newswire - PRF
Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs 1:07 p.m. Aug. 11, 2014 - PR Newswire - PRF
Amgen Receives CEO Cancer Gold Standard Accreditation 7:00 a.m. Aug. 11, 2014 - BusinessWire - BZX
Critical Alerts For Stratasys, Horizon Pharma, Isis Pharmaceuticals, Amgen, and Discover Financial Services Released By InvestorsObserver 9:31 a.m. Aug. 8, 2014 - PR Newswire - PRF
Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth 9:13 a.m. Aug. 5, 2014 - PR Newswire - PRF
Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies 11:55 a.m. Aug. 4, 2014 - PR Newswire - PRF
Earnings Headlines - Amgen 9:30 a.m. Aug. 4, 2014 - PR Newswire - PRF
Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼